New Report on Utilizing RWE in Drug Development Pipeline Throughout the Globe

A new report by consulting group Roots Analysis has been published. It features insight on RWE (real world evidence) when it comes to drug development and designing clinical trials. It also includes areas of therapeutic potential including cardiovascular disorders and autoimmune disorders. The report is aimed at leaders in pharmaceutical companies, payers, and other healthcare professionals.

“One of the key objectives of the report was to estimate the existing market size and future growth potential within the real world evidence market. We have developed informed estimates of the financial evolution of the market, over the period 2021-2030.” The report also includes: “A detailed analysis of completed, ongoing and planned clinical trials conducted in the real world setting based on the multiple parameters, such as trial status, trial registration year, regional distribution, enrolled patient population, type of study, leading industry and non-industry players, emerging focus areas and key therapeutic areas.” Learn more here.

(Source: Roots Analysis, January 2021)